Strategies to Optimize Multiple Myeloma Treatment With Carol Ann Huff, MD

Because multiple myeloma frequently remains asymptomatic until the disease is in the advanced stages, it can be difficult to diagnose and has limited treatment options, resulting in a five-year survival rate of only 50.7%. In this Q&A session from i3 Health's live meeting series, Evolving Treatment Paradigms in Multiple Myeloma and Implications for Shared Decision Making, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, discusses strategies to enhance the trea...
Continue reading

Treosulfan/Fludarabine Conditioning Improves Outcomes in HSCT

A recent phase 3 trial found that treosulfan/fludarabine used as conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (HSCT) led to greater event-free survival compared with busulfan/fludarabine in older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome.While patients age 50 or older with acute myeloid leukemia or myelodysplastic syndrome are often considered eligible for allogeneic HSCT, they are at increased risk from standard myeloablat...
Continue reading

Ibrutinib Increases Hypertension and Cardiovascular Risk

For patients with B-cell malignancies, the hypertension caused or worsened by treatment with ibrutinib results in a two-fold increased risk of major adverse cardiovascular events, report researchers at The Ohio State University.Ibrutinib can be highly effective against B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it also is associated with cardiotoxicity. Severe hypertension has been reported, but "the long-term incid...
Continue reading

Treating Multiple Myeloma: Challenges, Solutions, and Research Advances With Carol Ann Huff, MD

​With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who l...
Continue reading

When Should Ruxolitinib Be Used for Myelofibrosis or PV? With Srdan Verstovsek, MD, PhD

Myelofibrosis, a rare myeloproliferative neoplasm, can cause severe anemia, splenomegaly, and debilitating symptoms. It can present either as a primary condition or as a secondary condition following the transformation of essential thrombocythemia or polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow produces an excess of red blood cells and often of white blood cells and platelets. Last week at the Society of Hematologic Oncology (SOHO)'s Seventh Annual Meeting, Srdan ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.